Appliance of gabapentin in the treatment of neuropathic pain – a cases’ report Case report
Article Sidebar
Published:
Mar 31, 2019
Keywords:
neuropathic pain, neuropathies, pharmacotherapy
Main Article Content
Abstract
Neuropathic pain is caused by damage to the peripheral or central nervous system. It appears in the course of numerous diseases including diabetic polyneuropathy or polyneuropathy with a different etiology, trigeminal neuralgia, postherpetic neuralgia and root syndromes. A typical feature of neuropathic pain is poor response to standard analgesia. In the treatment of neuropathic pain, the first-line drugs are antiepileptic drugs (gabapentin and pregabalin, or carbamazepine) and antidepressants (amitriptyline and duloxetine). In the case of insufficient efficacy of the above drugs, the addition of acetaminophen or opioid (for example tramadol) may be considered. Non-steroidal anti-inflammatory drugs (NSAIDs) are not effective in the treatment of neuropathic pain [1, 2].
Article Details
How to Cite
Durka-Kęsy, M. A. (2019). Appliance of gabapentin in the treatment of neuropathic pain – a cases’ report. Medycyna Faktow (J EBM), 12(1(42), 44-47. https://doi.org/10.24292/01.MF.0119.8
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Szczudlik A., Dobrogowski J., Wordliczek J. et al.: Diagnosis and management of neuropathic pain: review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society – Part Two. Neurol. Neurochir. Pol. 2014; 48(6): 423-435. DOI: 10.1016/j.pjnns.2014.11.002.
2. Fornasari D.: Pharmacotherapy for Neuropathic Pain: A Review. Pain Ther. 2017; 6(supl. 1): S25-S33. DOI: 10.1007/s40122-017-0091-4.
3. Marais E., Klughauer N., Hofman F.: Calcium channel alpha (2) delta subunit structure and gabapentin binding. Mol. Pharmacol. 2001; 59: 1243-1248.
4. Qadeer M., Waqas M., Rashid M.J. et al.: Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. Asian Spine J. 2017; 11(1): 93-98. DOI: 10.4184/asj.2017.11.1.93.
5. Mangaiarkkarasi A., Rameshkannan S., Meher Ali R.: Effect of Gabapentin and Pregabalin in Rat Model of Taxol Induced Neuropathic Pain. J. Clin. Diagn. Res. 2015; 9(5): FF11-4.
6. Agarwal M.M., Elsi Sy M.: Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin? Neurourol. Urodyn. 2017; 36(8): 2028-2033. DOI: 10.1002/nau.23225.
7. Robertson K., Marshman L.A.G., Plummer D., Downs E.: Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic Sciatica: A Randomized Clinical Trial. JAMA Neurol. 2018. DOI: 10.1001/jamaneurol.2018.3077.
8. Handforth A., Treiman D.M.: Efficacy and tolerance of long-term, high-dose gabapentin: additional observations. Epilepsia 1994; 35(5): 1032-1037.
9. Moore A., Derry S., Wiffen P.: Gabapentin for Chronic Neuropathic Pain. JAMA 2018; 319(8): 818-819. DOI: 10.1001/jama.2017.21547.
10. Zhang M., Gao C.X., Ma K.T. et al.: A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. Biomed. Res. Int. 2018; 2018: 7474207. DOI: 10.1155/2018/7474207.
11. Rudroju N., Bansal D., Talakokkula S.T. et al.: Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013; 16(6): E705-14. Erratum in: Pain Physician. 2014; 17(2): 203.
12. Sills G.: The mechanism of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 2006; 6: 108-113.
13. Frampton J.E., Foster R.H.: Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005; 65: 111-118.
14. Frampton J.E., Scott L.J.: Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs 2004; 64: 2813-2820.
15. Fleet J.L., Dixon S.N., Kuwornu P.J. et al.: Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population- based study. PLoS One 2018; 13(3): e0193134. DOI: 10.1371/journal.pone.0193134. eCollection 2018.
16. Megna J.L., Devitt P.J., Sauro M.D., Dewan M.J.: Gabapentin’s effect on agitation in severely and persistently mentally ill patients. Ann. Pharmacother. 2002; 36: 12-16.
17. Chiappini S., Schifano F.: A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‚Suspected Adverse Drug Reactions’ Database. CNS Drugs 2016; 30(7): 647-54. DOI: 10.1007/s40263-016-0359-y.
18. Wiffen P.J., Derry S., Bell R.F. et al.: Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 2017; 6: CD007938. DOI: 10.1002/14651858.CD007938.pub4.
2. Fornasari D.: Pharmacotherapy for Neuropathic Pain: A Review. Pain Ther. 2017; 6(supl. 1): S25-S33. DOI: 10.1007/s40122-017-0091-4.
3. Marais E., Klughauer N., Hofman F.: Calcium channel alpha (2) delta subunit structure and gabapentin binding. Mol. Pharmacol. 2001; 59: 1243-1248.
4. Qadeer M., Waqas M., Rashid M.J. et al.: Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. Asian Spine J. 2017; 11(1): 93-98. DOI: 10.4184/asj.2017.11.1.93.
5. Mangaiarkkarasi A., Rameshkannan S., Meher Ali R.: Effect of Gabapentin and Pregabalin in Rat Model of Taxol Induced Neuropathic Pain. J. Clin. Diagn. Res. 2015; 9(5): FF11-4.
6. Agarwal M.M., Elsi Sy M.: Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin? Neurourol. Urodyn. 2017; 36(8): 2028-2033. DOI: 10.1002/nau.23225.
7. Robertson K., Marshman L.A.G., Plummer D., Downs E.: Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic Sciatica: A Randomized Clinical Trial. JAMA Neurol. 2018. DOI: 10.1001/jamaneurol.2018.3077.
8. Handforth A., Treiman D.M.: Efficacy and tolerance of long-term, high-dose gabapentin: additional observations. Epilepsia 1994; 35(5): 1032-1037.
9. Moore A., Derry S., Wiffen P.: Gabapentin for Chronic Neuropathic Pain. JAMA 2018; 319(8): 818-819. DOI: 10.1001/jama.2017.21547.
10. Zhang M., Gao C.X., Ma K.T. et al.: A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. Biomed. Res. Int. 2018; 2018: 7474207. DOI: 10.1155/2018/7474207.
11. Rudroju N., Bansal D., Talakokkula S.T. et al.: Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013; 16(6): E705-14. Erratum in: Pain Physician. 2014; 17(2): 203.
12. Sills G.: The mechanism of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 2006; 6: 108-113.
13. Frampton J.E., Foster R.H.: Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005; 65: 111-118.
14. Frampton J.E., Scott L.J.: Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs 2004; 64: 2813-2820.
15. Fleet J.L., Dixon S.N., Kuwornu P.J. et al.: Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population- based study. PLoS One 2018; 13(3): e0193134. DOI: 10.1371/journal.pone.0193134. eCollection 2018.
16. Megna J.L., Devitt P.J., Sauro M.D., Dewan M.J.: Gabapentin’s effect on agitation in severely and persistently mentally ill patients. Ann. Pharmacother. 2002; 36: 12-16.
17. Chiappini S., Schifano F.: A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‚Suspected Adverse Drug Reactions’ Database. CNS Drugs 2016; 30(7): 647-54. DOI: 10.1007/s40263-016-0359-y.
18. Wiffen P.J., Derry S., Bell R.F. et al.: Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 2017; 6: CD007938. DOI: 10.1002/14651858.CD007938.pub4.